By Pesach Benson • January 15, 2026
Yeruusaalem, 15 January, 2026 (TPS-IL) — Shirkadda tignoolajiyada bayoolojiga ee Immunai oo fadhigeedu yahay Tel Abiib ayaa heshiis la saxeexatay shirkadda dawooyinka ee Maraykanka ee Bristol Myers Squibb si ay u horumariso horumarinta dawooyinka iyadoo isticmaalaysa nidaamkeeda AI ee AMICA-OS. Madalkani wuxuu falanqeeyaa xogta difaaca jirka ee sare-cabbirka ah ee laga helo imtixaanada caafimaad si loo helo aragtiyo ku saabsan jawaabaha difaaca jirka ee bukaanka, taasoo taageerta helida biomarkers, u kala saarida bukaanka, iyo hagaajinta daawaynta.
"Iyada oo loo marayo shaqadeena Bristol Myers Squibb, waxaan u turjumi doonaa xogta difaaca jirka ee adag aragtiyo la fulin karo oo caawin kara horumarinta daawaynta wanaagsan," ayuu yiri Maamulaha Guud ee Immunai, Noam Solomon.
Mawduucyada La Xiriira
